Skip to main content
. 2015 Dec 8;7(3):2968–2984. doi: 10.18632/oncotarget.6502

Figure 1. OVCAR-3 cells are sensitive to NAMPT inhibition with FK866.

Figure 1

(A) Schematic representation of the rationale for simultaneously inhibiting CD73 and NAMPT. (B) Screening of the NAD+ biosynthetic enzyme activities performed on cell lysates from untreated OVCAR-3 cells (black bars) or from cells treated for 24 h with 30 nM FK866 (white bars). Results are mean ± SD of 3 determinations. *p < 0.001. (C) OVCAR-3 cells were incubated for 48 h with 30 nM FK866, in the presence of 10 μM NMN, NR, QA or of 100 μM PA. Results are mean ± SD of at least 3 determinations. *p < 0.01 compared to FK866 alone.